公开(公告)号：US09655902B2

公开(公告)日：2017-05-23

申请号：US14762542

申请日：2014-01-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  Ying Han ,  Zhiwei Yin ,  Paul Michael Scola

IPC: C07D251/52 ,  C07D403/14 ,  C07D403/12 ,  A61K31/53 ,  A61P31/14 ,  A61K31/551 ,  A61K45/06

CPC classification number: A61K31/53 ,  A61K31/551 ,  A61K45/06 ,  C07D251/52 ,  C07D403/12 ,  C07D403/14

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US09624245B2

公开(公告)日：2017-04-18

申请号：US14765910

申请日：2014-02-04

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  Zhiwei Yin ,  Li-Qiang Sun ,  Eric Mull ,  Qian Zhao ,  Paul Michael Scola

IPC: C07D519/00 ,  C07D498/22 ,  C07D498/08 ,  C07D498/18 ,  A61K31/53 ,  A61K31/551 ,  A61K45/06 ,  C07D498/20

CPC classification number: C07D498/22 ,  A61K31/53 ,  A61K31/551 ,  A61K45/06 ,  C07D498/08 ,  C07D498/18 ,  C07D498/20

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US09624180B2

公开(公告)日：2017-04-18

申请号：US14762554

申请日：2014-01-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Zhongxing Zhang ,  Paul Michael Scola

IPC: C07D251/52 ,  A61K31/53 ,  C07D403/12 ,  A61P31/14 ,  A61K45/06

CPC classification number: C07D251/52 ,  A61K31/53 ,  A61K45/06 ,  C07D403/12

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US09422311B2

公开(公告)日：2016-08-23

申请号：US14433841

申请日：2013-10-15

Applicant: Bristol-Myers Squibb Company

Inventor： Tao Wang ,  Zhongxing Zhang ,  Eric P. Gillis ,  Paul Michael Scola

IPC: A61K31/53 ,  C07D498/16 ,  C07D498/06 ,  C07D498/08 ,  C07D498/22

CPC classification number: C07D498/06 ,  C07D498/08 ,  C07D498/16 ,  C07D498/22

Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US09249152B2

公开(公告)日：2016-02-02

申请号：US14663497

申请日：2015-03-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Kyle J. Eastman ,  Zhongxing Zhang ,  Kyle E. Parcella ,  Zhiwei Yin ,  John F. Kadow

IPC: C07D491/048 ,  C07D491/04

CPC classification number: C07D491/048 ,  C07D491/04

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:

Abstract translation: 阐述了式I化合物，包括它们的盐，以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者：

公开(公告)号：US20150266886A1

公开(公告)日：2015-09-24

申请号：US14663497

申请日：2015-03-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  Kyle J. Eastman ,  Zhongxing Zhang ,  Kyle E. Parcella ,  Zhiwei Yin ,  John F. Kadow

IPC: C07D491/048

CPC classification number: C07D491/048 ,  C07D491/04

Abstract: Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:

Abstract translation: 阐述了式I化合物，包括它们的盐，以及使用该化合物的组合物和方法。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者：

公开(公告)号：US20150232463A1

公开(公告)日：2015-08-20

申请号：US14619438

申请日：2015-02-11

Applicant: Bristol-Myers Squibb Company

Inventor： B. Narasimhulu Naidu ,  Manoj Patel ,  Jeffrey Lee Romine ,  Denis R. St. Laurent ,  Tao Wang ,  Zhongxing Zhang ,  John F. Kadow

IPC: C07D417/14 ,  C07D413/14 ,  C07D409/14 ,  C07D401/04 ,  C07D401/14

CPC classification number: C07D417/14 ,  C07D213/61 ,  C07D401/04 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

Abstract: The disclosure generally relates to compounds of formula I, II, III and IV, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

Abstract translation: 本公开一般涉及式I，II，III和IV的化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。 本公开提供了HIV的新型抑制剂，含有这些化合物的药物组合物，以及使用这些化合物治疗HIV感染的方法。

公开(公告)号：US20150190387A1

公开(公告)日：2015-07-09

申请号：US14419564

申请日：2013-08-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao Wang ,  John F. Kadow ,  Nicholas A. Meanwell ,  Zhongxing Zhang ,  Zhiwei Yin ,  Edward H. Ruediger ,  Clint A. James ,  Daniel H. Deon

IPC: A61K31/4545 ,  C07D401/14 ,  C07D401/06 ,  A61K31/454 ,  C07D471/04 ,  A61K45/06

CPC classification number: A61K31/4545 ,  A61K31/454 ,  A61K45/06 ,  C07D401/06 ,  C07D401/14 ,  C07D471/04

Abstract: Compounds of Formula (I), including pharmaceutically acceptable salts thereof: wherein A is selected from the group consisting of: and wherein Z is: are useful as HIV attachment inhibitors.

Abstract translation: 式（I）的化合物，包括其药学上可接受的盐：其中A选自：并且其中Z是：可用作HIV附着抑制剂。

公开(公告)号：US08871771B2

公开(公告)日：2014-10-28

申请号：US13861804

申请日：2013-04-12

Applicant: Bristol-Myers Squibb Company

Inventor： Yasutsugu Ueda ,  Timothy P. Connolly ,  John F. Kadow ,  Nicholas A. Meanwell ,  Tao Wang ,  Chung-Pin H. Chen ,  Kap-Sun Yeung ,  Zhongxing Zhang ,  David Kenneth Leahy ,  Shawn K. Pack ,  Nachimuthu Soundararajan ,  Pierre Sirard ,  Kathia Levesque ,  Dominique Thoraval

IPC: A61K31/497 ,  C07D401/00

CPC classification number: A61K31/675 ,  A61K31/497 ,  A61K45/06 ,  C07D471/04 ,  C07F9/062 ,  C07F9/5728 ,  C07F9/65515 ,  C07F9/65586 ,  C07F9/6561

Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

Abstract translation: 本发明提供前药化合物I，其药物组合物及其在治疗HIV感染中的用途。 其中：X为C或N，条件是当X为N时，R1不存在; W为C或N，条件是当W为N时，R2不存在; V是C; E是氢或其药学上可接受的盐; 并且Y选自本发明另外，本发明提供了可用于制备前药化合物I的中间体化合物II。其中：L和M独立地选自C 1 -C 6烷基，苯基，苄基，三烷基甲硅烷基， 2,2,2-三氯乙氧基和2-三甲基甲硅烷基乙氧基。

公开(公告)号：US20130289046A1

公开(公告)日：2013-10-31

申请号：US13858624

申请日：2013-04-08

Applicant: Bristol-Myers Squibb Company

Inventor： TAO WANG ,  Zhongxing Zhang ,  Nicholas A. Meanwell ,  John F. Kadow ,  Zhiwei Yin ,  Qiufen May Xue ,  Alicia Regueiro-Ren ,  John D. Matiskella ,  Yasutsugu Ueda

IPC: A61K31/496 ,  A61K45/06

CPC classification number: C07D471/04 ,  A61K31/496 ,  A61K45/06 ,  C07D491/048

Abstract: This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.